SS11 : Late-Breaking Clinical Trials

Updated:Feb 22,2013
web masthead-SS11


Late-Breaking Clinical Trials

LBCT.01 - Sunday, Nov. 13   |   LBCT.02/03 - Monday, Nov. 14
LBCT.04 - Tuesday, Nov. 15   |   LBCT.05 - Wednesday, Nov. 16

AIDA STEMIISAR-REACT 4ADOPTTRA•CER
ATLAS ACS 2- TIMI 51Post-MI FREEEHOOPSEvidence-Based, Individualized
Informed Consent Form
CPORT EALPHEEFASTMANTRA-PAF
PALLASAIM-HIGHPOWER SATURN
 Lipid-Modulating Effects of EvacetrapibEASECLEVERCOPPS Atrial Fibrillation
ELEVATE-TIMI 56 SCIPIO  


LBCT.01 - Sun., Nov. 13, 3:45 p.m.
Holger Thiel
Holger Thiele, MD  
Herzzentrum Leipzig,
Leipzig, Germany
AIDA-STEMI 
Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention: AIDA STEMI Trial 

Discussant: Alice K. Jacobs, MD, FAHA, Boston, Mass.

Presentation slides  |  Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
 |  Summary slide  |  News release
Video interview  |  Abstract

Adnan Kasrati
Adnan Kastrati, MD  
Deutsches Herzzentrum, Munich, Germany
ISAR-REACT 4 
Abciximab Plus Unfractionated Heparin versus Bivalirudin in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. The ISAR-REACT 4 Randomized Trial 

Discussant: Deepak Bhatt, MD, MPH, FAHA, Boston, Mass.

Presentation slides  |  Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
|  Summary slide  |  News release
Abstract

Samuel Z Goldhabo 
Samuel Z. Goldhaber, MD
Brigham and Women's Hospital, Boston, Mass.
ADOPT
Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial 

Discussant: Mary Cushman, MD, MSc, FAHA, Colchester, Va.

Presentation slides  |  Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
Summary slide  |  News release
Abstract
Kenneth W Mahaf
Kenneth W. Mahaffey, MD  
Duke Clinical Res Institute, Durham, N.C.
TRA•CER
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) Trial 

Discussant: Keith A.A. Fox, MB, ChB, Edinburgh, United Kingdom  

Presentation slides  |  Presentation audio
Play Audio
  |  Summary slide
News release  |   Video interview  |  Abstract
C Michael Gibson
C. Michael Gibson, MD  
Beth Israel Deaconess Medicine Center, Boston, Mass.
ATLAS ACS 2- TIMI 51
Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome 

Discussant: Paul W. Armstrong, MD, FAHA, Edmonton, AB, Canada 

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  News release
Video interview  |  Abstract
LBCT.02 - Mon., Nov. 14, 10:45 a.m.
niteesh k choudhr 
Niteesh K. Choudhry,
MD, PhD  
Harvard Medical School, Boston, Mass.
Post-MI FREEE
The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial 

Discussant: Eric D. Peterson, MD, MPH, FAHA, Durham, N.C.

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  News release
Video interview  |  Abstract


richard lowrie
Richard Lowrie, MD 
 
National Health Service, Greater Glasgow and Clyde, Glasgow, United Kingdom  
HOOPS 
Pharmacist Intervention to Prevent Hospitalization and Death in Patients with Heart Failure: A Prospective Cluster Randomised Controlled Trial 

Discussant: Mariell Jessup, MD, FAHA, Philadelphia, Pa.

Presentation slides  |  Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  News release
  Abstract
john spertus 
John Spertus, 
MD, MPH, FAHA 
 
Mid America Heart Institute, Kansas City, Mo.
Evidence-Based, Individualized Informed Consent Form
Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients' Experiences with PCI 

Discussant: Manesh R. Patel, MD, Durham, N.C.

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
  |  Summary slide  |  News release
Abstract
thomas aversano
Thomas Aversano, MD  
Johns Hopkins Medical Institutions, Baltimore, Md.  
CPORT E
Outcomes of Non-Primary PCI at Hospitals with and Without On-Site Cardiac Surgery: A Randomized Study 

Discussant: Loren F. Hiratzka, MD, FAHA

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
  |  Summary slide  |  News release
Video interview  |  Abstract
LBCT.03 - Mon., Nov. 14, 3:45 p.m.
 ss10_LBCT02_Kowey
Peter R. Kowey, MD  
MLH Heart Center Lankenau Medical Center,
Wynnewood, PA
 
ALPHEE
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE) 

Discussant: Cynthia M. Tracy, MD, FAHA, Washington, D.C. 

Presentation slides  |  Presentation audio
Play Audio
Discussant audio
Play Audio

Discussant slides
 |  Summary slide  |  Video interview
Lucas Boersma 
Lucas Boersma, MD, PhD  
St. Antonius Hospital, Nieuwegein, Netherlands
FAST
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: a Multi-center Randomized Clinical Trial 

Discussant: A. Marc Gillinov, MD, FAHA, Cleveland, Ohio

Presentation slides  |  Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
  |  Summary slide  |  Video interview
Jens Cosedis Nielsen
 Jens Cosedis Nielsen, 
MD, PhD
  
Aarhus University Hospital, Skejby, Aarhus N, Denmark
MANTRA-PAF
A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First-Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation 

Discussant: William G. Stevenson, MD, FAHA, Boston, Mass.

Presentation slides  |  Discussant slides  |  Presentation audio
Play Audio

Discussant audio
Play Audio
  |   Summary slide  |  Video interview
Stuart J 
Stuart J. Connolly, MD  
Hamilton General Hospital, Hamilton, ON, Canada
PALLAS
The Results of the PALLAS Study: PALLAS was designed to test whether dronedarone could reduce major vascular morbidity and mortality in patients with permanent atrial fibrillation and previous vascular disease or multiple risk factors.

Discussant: Mark Estes III, MD, FAHA, Boston, Mass.

Presentation slides  |  Presentation audio
Play Audio
|  Discussant slides Discussant audio
Play Audio
  |   Summary slide 
LBCT.04 - Tues., Nov. 15, 10:45 a.m.
 William E
William E. Boden, MD, FAHA
University of Buffalo,
Buffalo, N.Y.
AIM-HIGH
Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial 

Discussant: Philip Barter, MD, PhD, Sydney Nsw, Australia  

Presentation slides  |  Presentation audio
Play Audio
  |   Discussant slides 
Discussant audio
Play Audio
 |  Summary slide  |  Video interview  
 Lawrence J
Lawrence J. Appel,
MD, MPH, FAHA

Johns Hopkins Medical Institutes University,
Baltimore, MD
POWER
Practice-Based Opportunities for Weight Reduction (POWER) 

Discussant: Frank Sacks, MD, FAHA, Boston, Mass.

Presentation slides  |  Presentation audio
Play Audio
  |   Discussant slides 
Discussant audio
Play Audio
 |  Summary slide  |  Video interview  
 Stephen J
Stephen J. Nicholls, PhD
Cleveland Clinic,
Cleveland, Ohio
SATURN
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results 

Discussant: Darwin Labarthe, MD, MPH, PhD, FAHA, Chicago, Ill.

Presentation slides  |  Presentation audio
Play Audio
  |   Discussant audio
Play Audio
Summary slide  |  Video interview  
 Stephen J
Stephen J. Nicholls, PhD
Cleveland Clinic,
Cleveland, Ohio
Lipid-Modulating Effects of Evacetrapib
Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins 

Discussant: Daniel J. Rader, MD, FAHA, Philadelphia, Pa.

Presentation slides  |  Presentation audio
Play Audio
  |   Discussant slides 
Discussant audio
Play Audio
 |  Summary slide  |  Video interview
 
LBCT.05 - Wed., Nov. 16, 10:45 a.m.
 Duk-HyunKang
Duk-Hyun Kang, MD, PhD  
Asan Medical Ctr, Seoul, Korea, Republic of
EASE
Randomized Trial of Early Surgery versus Conventional Treatment for Infective Endocarditis (EASE) 

Discussant: Robert S. Higgins, MD, Columbus, Ohio

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  Video interview
AlanHirschforTimothyPMurphy
Alan T. Hirsch, MD  
University of Minnesota, 
Minneapolis, MN 
CLEVER
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes From the CLEVER Study 

Discussant: Michael S. Conte, MD, San Francisco, Calif. 

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  Video interview
MassimoImazio
Massimo Imazio, MD
Maria Vittoria Hospital,
Torino, Italy
 
COPPS Atrial Fibrillation
Colchicine Reduces Post-Operative Atrial Fibrillation. Results of the COPPS Atrial Fibrillation Study   

Discussant: Nancy Nussmeier, MD, FAHA, Syracuse, N.Y.

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  Video interview
JessicaMega
 Jessica L. Mega, MD, MPH  
Brigham and Women's Hospital, Boston, Mass.
ELEVATE-TIMI 56
ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56 

Discussant: Lawrence J. Lesko, PhD, Orlando, Fla.  

Presentation slides  | Presentation audio
Play Audio
  |  Discussant slides 
Discussant audio
Play Audio
| Summary slide  |  Video interview
roberto boli
Roberto Bolli, MD, FAHA
University of Louisville,
Louisville, Ky.
SCIPIO
Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial





Connect with AHA Science News

Follow AHAScience on Twitter (opens in new window)
Like AHA Science News on Facebook (opens in new window)

SS11: Programs and Events

  • ss11_ad_dailynews
  • ss11_ad_ress2012
  • ss11_ad_ss2012
  • ss11_ad_sessionsondemand
  • ss11_ad_corecollection
  • ss11_ad_sciencenews

Don’t miss: late-breaking Science News from Scientific Sessions 2011

Science News: Why I Subscribe

  • ss11_sn_gordontomaselli
  • ss11_sn_RobertHarrington
  • ss11_sn_elliottantman
  • ss11_sn_mikhailkosiborod

Why I Subscribe to Science News: Mikhail Kosiborod, MD, FAHA

The Cardiovascular Daily

Become A Member

Become a professional member of the American Heart Association/American Stroke Association.

Join or renew your AHA/ASA Professional Membership
to qualify for members-only awards, and:

• Affiliate with one of 16 Scientific Councils.
• Save on AHA/ASA Scientific Sessions.
• Save on print publications.
• Apply for research funding and not pay a fee
• Enjoy many more membership benefits.

Promo code: WDJ008ZZ

Claim CME/CE Credit

CME CE Accreditation Image

Have you just attended an AHA session? 
Claim CME/CE Certificates of Credit online now at the Professional Education Center.

CME/CE Credit now available for the following Sessions:
    • All 2011 Scientific Sessions
    • International Stroke Conference
          (available Feb. 17)
    • State-of-the-Art Stroke Nursing Symposium
          (available Feb. 17)
    • ISC Pre-conference Symposium
          (available Feb. 17)